All In Biotech

Free tool

FAERS Monitor: Brevibloc

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019386 or its brand name (Brevibloc, Esmolol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

267

Serious

251

94% of reports

Hospitalization

94

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective36
  • cardiac arrest21
  • hypotension20
  • bradycardia17
  • product use issue15
  • product use in unapproved indication12
  • renal failure10
  • ventricular fibrillation10
  • hypertension9
  • acute kidney injury8
  • atrial fibrillation8
  • death8
  • hepatotoxicity8
  • hyperbilirubinaemia8
  • pulmonary oedema8

Reports by year received

View as table
YearReports
20046
20056
20065
20077
20084
200910
20106
201114
20126
20139
20147
201521
201617
201710
201815
201914
202013
202116
202214
202321
202411
202526
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,892 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ventricular fibrillationSignal1071.038.6621
hyperbilirubinaemiaSignal860.930.8413
hepatotoxicitySignal828.314.3184
bradycardiaSignal1725.315.9373
cardiac arrestSignal2120.013.3362
pulmonary oedemaSignal814.17.185
hypotensionSignal207.95.2114
atrial fibrillationSignal86.53.332
product use issueSignal156.33.862
renal failureSignal105.93.236
acute kidney injurySignal84.12.116
product use in unapproved indicationSignal123.82.222
hypertensionSignal93.31.813
drug ineffectiveSignal362.21.622
death80.70.41

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.